As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
Corey Ford
Advertisement
Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.
Articles by Corey Ford
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Merck Begins Construction on $3 Billion Pharmaceutical Center of Excellence in Virginia
2
HDA 2025 Traceability Seminar: FDA Emphasizes Readiness Over Perfection
3
